Fulcrum Therapeutics, Inc.

Good morning and welcome to the Fulcrum Therapeutics second quarter 2022 conference call. Currently, all participants are in listen-only mode. There will be a question and answer session at the end of this call. Please note, today's conference is being recorded. I would now like to turn the call over to Stephanie Asher from Stern Investor Relations. Please proceed.

Thank you, Rocco. Good morning and welcome to the Fulcrum Therapeutics Conference Call. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development timelines, and financial projections. While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on an obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with our business. With me on today's call are Brian Stewart, President and Chief Executive Officer, Judy Dunn, our President of Research and Development, and Esther Rajavelu, our Chief Financial Officer. In addition, Paul Bruno, our Executive Director of Corporate Development, will be available for Q&A. Let me quickly run through this morning's agenda. Brian will begin the call with a corporate overview and key updates. Judy will review our clinical program. Esther will cover our financials. And then Brian will open the call for Q&A. With that, it's my pleasure to turn the call over to Brian.

Thank you, Stephanie.